THIS ANNOUNCEMENT RELATES TO AN OFFERING OF SECURITIES THAT HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, ANY U.S. STATE SECURITIES LAWS OR THE LAWS OF ANY JURISDICTION AND WILL BE OFFERED AND SOLD TO QUALIFIED INSTITUTIONAL BUYERS PURSUANT TO RULE 144A, AND IN COMPLIANCE WITH REGULATION S OUTSIDE THE UNITED STATES (EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT). THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE U.S. OR TO U.S. PERSONS ABSENT REGISTRATION OR AN APPLICABL ...

Core Insights - Serina Therapeutics, Inc. has announced a strategic partnership with Juvenescence Ltd., which has successfully closed the first tranche of a $76 million Series B financing round, targeting a total of $150 million [2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the development of innovative therapeutics [3][4] - Serina is focused on developing its proprietary POZ Platform™ for drug optimization, targeting neurological diseases and other indications, and is positioned as a core portfolio company of Juvenescence [5][4] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, specializing in drug candidates for neurological diseases and other conditions [5] - The POZ Platform™ developed by Serina has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [5] - Juvenescence, the strategic partner, is an AI-enabled biotech company focused on developing medicines to extend healthy lifespan by targeting aging mechanisms [7][9] Strategic Partnerships - The collaboration between Juvenescence and M42, a global health company based in Abu Dhabi, signifies a commitment to building a leading life-sciences hub and developing a pipeline of innovative therapeutics [4][11] - M42 operates over 480 facilities across 26 countries and employs more than 20,000 people, integrating advanced technologies in healthcare [12]

The earlier part of the year wasn't easy for market superstar Nvidia (NVDA -0.41%). The stock slumped for a few reasons -- from worries about U.S. export controls on artificial intelligence (AI) chips for the Chinese market and a U.S. plan to set tariffs on imports, to concerns about technology spending. Each of these areas represents a risk for the leading AI chip designer, and that kept the stock trading well below $150. In fact, at its lowest, Nvidia slipped to less than $100 earlier in the year. But, in ...

Core Insights - Ascletis Pharma Inc. has initiated a Phase I clinical trial for ASC50, an oral small molecule inhibitor targeting interleukin-17 (IL-17), aimed at treating psoriasis [2][3] - The trial is randomized, double-blind, and placebo-controlled, involving both healthy participants and patients with mild-to-moderate plaque psoriasis [3] - Preclinical data suggests that ASC50 has higher oral exposure, a longer half-life, and strong efficacy, positioning it as a potential best-in-class treatment for psoriasis [1] Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing innovative therapeutics for metabolic diseases [4] - The company utilizes its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP) to develop drug candidates in-house [4] - Ascletis is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [4]

SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science- based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature ri ...

Company Overview - Canadian Critical Minerals Inc. (CCMI) is a mining company focused on copper production assets in Canada [2] - The main asset of CCMI is the Bull River Mine project, which contains 150 million lbs of copper, located near Cranbrook, British Columbia [2] - CCMI also holds a 10% interest in XXIX Metal Corp., which owns the Thierry copper project in Ontario and the Opemiska copper project in Quebec [2] Recent Developments - Chris Stewart has resigned as a director of CCMI for personal reasons, effective June 16, 2025 [1] - Ian Berzins, President and CEO of CCMI, expressed gratitude for Mr. Stewart's service and contributions to the company [1]

Company Overview - Hasbro has cut 3% of its global workforce, amounting to approximately 150 employees, as part of a cost-cutting initiative due to higher US tariffs on toys imported from China [1][4] - The company had around 4,985 employees globally according to its fiscal 2024 annual filing [1] Sourcing and Market Strategy - Hasbro sources about half of its toys and games sold in the US from China and is accelerating efforts to diversify sourcing to reduce reliance on China [2] - The toy industry is facing pressures from a global trade war and has been struggling with weak demand [2] Financial Impact and Restructuring - CEO Chris Cocks indicated that tariffs lead to higher consumer prices, potential job losses, and reduced profits for shareholders [3] - Hasbro is reassessing logistics routes and manufacturing as part of its strategy to adapt to increased costs [3] - The company previously announced a plan to cut 900 jobs globally in December 2023, following a reduction of 15% of its workforce due to weaker sales [3] Business Performance - In April, Hasbro reported better-than-expected quarterly results, driven by a shift towards digital and licensed gaming businesses, which helped attract younger customers [5]

Company Performance - Whirlpool's stock closed at $91.27, reflecting a -1.91% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.84% [1] - Over the past month, Whirlpool's shares have appreciated by 12.56%, outperforming the Consumer Discretionary sector's loss of 0% and the S&P 500's gain of 1.44% [1] Upcoming Earnings - The company's earnings report is scheduled for July 28, 2025, with an anticipated EPS of $1.64, indicating a 31.38% decline compared to the same quarter last year [2] - Projected revenue for the upcoming quarter is $3.84 billion, reflecting a 3.8% decrease from the equivalent quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of $8.68 per share and revenue of $15.5 billion, representing changes of -28.91% and -6.7% respectively from the previous year [3] - Recent changes to analyst estimates for Whirlpool may indicate shifting near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Valuation Metrics - Whirlpool has a Forward P/E ratio of 10.72, which aligns with the industry average Forward P/E of 10.72 [6] - The Household Appliances industry, part of the Consumer Discretionary sector, holds a Zacks Industry Rank of 193, placing it in the bottom 22% of over 250 industries [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5] - Currently, Whirlpool holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having moved 0.81% higher over the past month [5]

Company Performance - Astera Labs, Inc. (ALAB) stock decreased by 2.51% to $92.91, underperforming the S&P 500's daily loss of 0.84% [1] - Over the last month, ALAB shares increased by 5.23%, outperforming the Computer and Technology sector's loss of 0% and the S&P 500's gain of 1.44% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of $0.33, representing a 153.85% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $172.71 million, up 124.74% from the year-ago period [2] Full-Year Estimates - Full-year Zacks Consensus Estimates predict earnings of $1.35 per share and revenue of $702.43 million, indicating year-over-year changes of +60.71% and +77.25%, respectively [3] - Recent changes to analyst estimates for Astera Labs are seen as a sign of optimism regarding the business outlook [3] Zacks Rank and Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Astera Labs at 2 (Buy) [5] - Over the past month, there has been a 2.74% rise in the Zacks Consensus EPS estimate [5] Valuation Metrics - Astera Labs is currently trading at a Forward P/E ratio of 193.92, significantly higher than the industry average of 45.44 [6] - The company has a PEG ratio of 4.48, compared to the Internet - Software industry's average PEG ratio of 3.23 [6] Industry Context - The Internet - Software industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 47, placing it in the top 20% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - VirTra, Inc. (VTSI) closed at $6.21, with a daily increase of +1.14%, outperforming the S&P 500's loss of 0.84% [1] - Prior to the recent trading day, shares had gained 3.54%, while the Aerospace sector remained flat [1] Earnings Expectations - The upcoming earnings disclosure is expected to show an EPS of $0.03, a decrease of 72.73% from the prior-year quarter [2] - Revenue is projected at $6.38 million, reflecting an increase of 5.11% from the prior-year quarter [2] Full Year Projections - For the full year, earnings are projected at $0.27 per share, representing a 125% increase from the prior year [3] - Revenue for the full year is estimated at $29.19 million, indicating a growth of 7.9% from the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for VirTra, Inc. are seen as a reflection of the business outlook [3] - The Zacks Rank system currently rates VirTra, Inc. as 1 (Strong Buy), indicating positive sentiment [5] Valuation Metrics - VirTra, Inc. has a Forward P/E ratio of 22.74, which aligns with the industry average [6] - The Electronics - Military industry, part of the Aerospace sector, holds a Zacks Industry Rank of 1, placing it in the top 1% of over 250 industries [6] Industry Performance - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]